{{header
 | author     = 
 | related_author = United States Congress
 | translator = 
 | section    = 
 | previous   = 
 | next       = 
 | year       = 
 | month      = 
 | day        = 
 | notes      = ''{{USBill|113|S.|1128}}'' as introduced
 | categories =
 | portal     =
 | congress   = 113
 | session    = 1
 | title      = Preserving Access to Orphan Drugs Act of 2013 ( S. 1128; 113th Congress)
 | bill       = 1128
 | billtype   = s
 | purpose    = To clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers.
 | wikipedia  =
}}
      
{{Center|113th CONGRESS}}

 
{{Center|1st Session}}

 
{{Center|S. 1128}}

 
{{Center|IN THE SENATE OF THE UNITED STATES}}

  
{{Center|June 11, 2013}}

 
{{Center| 
[[w:|Mr. Toomey]](for himself,
[[w:|Mr. Casey]], and
[[w:|Mr. Crapo]]) introduced the following bill; which was read twice and referred to the [[w:United States Senate Committee on Finance|Committee on Finance]] }}

  
{{Center|A BILL}}

 To clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers.   

=Section 1. Short title=

This Act may be cited as the“ Preserving Access to Orphan Drugs Act of 2013 ”. 

=Sec. 2. Clarification of orphan drug exception to annual fee on branded prescription pharmaceutical manufacturers and importers=



==(a) In general– ==

   Paragraph (3) of section 9008(e) of the Patient Protection and Affordable Care Act ([http://www.law.cornell.edu/uscode/text/26/4001  [http://www.law.cornell.edu/uscode/text/26/4001 26 U.S.C. 4001]note prec].;[[Public Law -|Public Law 111–148]])is amended to read as follows:

<blockquote> 

===(3) Exclusion of orphan drug sales– ===



====(A) In general– ====

The term branded prescription drug sales shall not include sales of any drug or biological product—
:(i) with respect to which a credit was allowed for any taxable year under   section 45C of the Internal Revenue Code of 1986   ; or
:(ii) which is approved or licensed by the [[w:Food and Drug Administration|Food and Drug Administration]]for marketing solely for one or more rare diseases or conditions.

====(B) Limitation– ====

  Subparagraph (A) shall not apply with respect to any drug or biological product after the date on which the drug or biological product is approved or licensed by the [[w:Food and Drug Administration|Food and Drug Administration]]for marketing for any indication other than the treatment of a rare disease or condition.

====(C) Rare disease or condition– ====

In this paragraph, the term rare disease or condition has the meaning given such term under   section 45C(d)(1) of the Internal Revenue Code of 1986   , except that in the case of any drug or biological product that has not been designated under   section 526 of the Federal Food, Drug and Cosmetic Act   for a particular indication, determinations under such section 45C(d)(1) shall be made on the basis of the facts and circumstances as of the date such drug or biological product is approved or licensed by the [[w:Food and Drug Administration|Food and Drug Administration]]for marketing for the treatment of such disease or condition. . 
</blockquote>


==(b) Effective date– ==

The amendment made by this section shall take effect as if included in  section 9008 of the Patient Protection and Affordable Care Act ([http://www.law.cornell.edu/uscode/text/26/4001 26 U.S.C. 4001 note prec].;[[Public Law -|Public Law 111–148]] ).  
{{PD-USGov}}
[[Category:Proposed United States federal law]]
[[Category:Proposed United States federal law of the 113th Congress]]
